Completed PHASE3 INTERVENTIONAL NCT00259766

SHARE - Symbicort and Health Economics in a Real Life Evaluation

Symbicort and Health Economics in a Real Life Evaluation - SHARE - A Randomised, Open-Label, Parallel-Group, Multicentre Study to Assess the Asthma-Related Health-Care Costs, in Ordinary Clinical Practice During 12 Months

Sponsor: AstraZeneca

Conditions Asthma

Interventions Budesonide Formoterol Terbutaline

Updated 7 times since 2017 Last updated: Jan 21, 2011 Started: Apr 30, 2004 Completion: May 31, 2007

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00259766, this PHASE3 trial focuses on Asthma and remains completed. Sponsored by AstraZeneca, it has been updated 7 times since 2004, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

7 versions recorded

Jan 2026 — Present [monthly]

Completed PHASE3
Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3

▶ Show 2 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Apr 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

AstraZeneca

Data source: AstraZeneca

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Alingsås, Sweden , Angered, Sweden , Arlöv, Sweden , Arvidsjaur, Sweden , Arvika, Sweden , Bandhagen, Sweden , Boden, Sweden , Borensberg, Sweden , Bro, Sweden , Brunflo, Sweden and 98 more locations